Photobiomodulation for Age-Related Macular Degeneration
Photobiomodulation (PBM) shows promise as an emerging treatment for intermediate dry AMD based on recent high-quality trial data, though it is not yet included in established clinical practice guidelines and evidence remains mixed.
Current Guideline-Based Standard of Care
The most recent ophthalmology practice guidelines 1 establish clear treatment pathways for AMD that do not include PBM:
For Intermediate/Dry AMD:
- AREDS2 supplementation (vitamin C, vitamin E, zinc, copper, lutein, zeaxanthin) remains the only guideline-recommended intervention to slow progression 1
- Smoking cessation counseling is strongly recommended 1
- Regular monitoring for progression to advanced disease
For Neovascular (Wet) AMD:
- Anti-VEGF therapy is the established standard of care and should be initiated immediately upon diagnosis 1, 2
- Treatment within 2 years of diagnosis reduces legal blindness and visual impairment 1
Emerging Evidence for PBM
Most Recent High-Quality Study (2026):
The LIGHTSITE III trial 3 represents the strongest single study supporting PBM efficacy:
- Primary endpoint met: +6.2 letter gain at 21 months (p=0.0036)
- Visual improvement: 61.5% of eyes gained ≥5 letters, 23.1% gained ≥10 letters
- Disease modification: Significant reduction in progression to geographic atrophy (6.8% vs 24.0% in sham; p=0.007)
- Safety: No phototoxicity observed
- Treatment protocol: Multiwavelength (590,660,850 nm), 9 treatments over 3-5 weeks, repeated every 4 months for 24 months
Supporting Evidence:
A 2026 multicenter RCT 4 corroborated these findings:
- Significant reduction in drusen volume (-0.03 mm³ vs +0.02 mm³; p<0.001)
- BCVA improvement of +3.75 letters between groups (p=0.0001)
- No progression to neovascular AMD in PBM group vs 4 eyes in sham (p=0.044)
Contradictory Evidence:
A 2025 systematic review and meta-analysis 5 found no significant benefit:
- BCVA: SMD -0.30 (95% CI -0.85 to 0.26, p=0.30)
- Drusen volume: SMD -0.08 (95% CI -0.52 to 0.37, p=0.74)
- High heterogeneity (I²=83%) suggests variable study quality and protocols
Clinical Decision Algorithm
When to Consider PBM (Based on Current Evidence):
Eligible Patients:
- Bilateral intermediate dry AMD (AREDS category 3-4)
- Large drusen (≥125 μm) with pigmentary changes
- BCVA between 20/32 and 20/100
- No geographic atrophy or neovascular AMD
- High risk for progression (family history, smoking history, bilateral disease)
Treatment Protocol (if pursuing):
- Multiwavelength PBM (590,660,850 nm wavelengths)
- Initial series: 9 treatments, 3x/week over 3-5 weeks
- Maintenance: Repeat series every 4 months
- Duration: Minimum 12-24 months for disease-modifying effects
Monitoring:
- Baseline and serial OCT for drusen volume and geographic atrophy
- BCVA at each treatment cycle
- Amsler grid home monitoring for metamorphopsia
- Watch for conversion to neovascular AMD (requires immediate anti-VEGF)
Critical Caveats:
Do NOT use PBM for:
- Neovascular (wet) AMD → Use anti-VEGF immediately 1, 2
- Advanced geographic atrophy (limited evidence of benefit)
- Early AMD without high-risk features (insufficient evidence)
Continue guideline-based care regardless:
- AREDS2 supplementation should be maintained 1
- Smoking cessation remains critical 1
- Regular comprehensive eye examinations 1
Evidence Quality Assessment
Strengths:
- LIGHTSITE III 3 is a well-designed, double-masked RCT with 24-month follow-up
- Consistent findings across multiple 2026 studies 3, 4, 6
- Clinically meaningful outcomes (vision improvement, GA reduction)
- Excellent safety profile across all studies
Weaknesses:
- Not included in any current ophthalmology practice guidelines 1, 2
- Meta-analysis 5 shows high heterogeneity and no overall benefit
- Limited long-term data beyond 24 months
- Cost-effectiveness uncertain despite modeling 7
- Variable treatment protocols across studies
Practical Recommendation
For intermediate dry AMD patients at high risk for progression, PBM may be considered as an adjunct to guideline-based care (AREDS2 supplementation and monitoring), but should not replace established treatments. The most compelling evidence is the 71.7% reduction in geographic atrophy progression at 24 months 3, which represents a potentially disease-modifying effect not available with current guideline-recommended therapies.
However, anti-VEGF therapy remains the only proven treatment for neovascular AMD 1, 2, and any patient developing wet AMD must transition immediately to standard anti-VEGF treatment regardless of prior PBM use.
The discordance between individual trials 3, 4 and meta-analysis 5 suggests that treatment protocols, patient selection, and device specifications matter significantly. If pursuing PBM, use protocols matching successful trials (multiwavelength, specific treatment intervals).